We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of TCA Effect on Varicella Atrophic Scars

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00422539
Recruitment Status : Unknown
Verified January 2007 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : January 17, 2007
Last Update Posted : January 17, 2007
Information provided by:
Shahid Beheshti University of Medical Sciences

Brief Summary:
This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella

Condition or disease Intervention/treatment Phase
Atrophic Varicella Scar Drug: 70% trichloroacetic acid Phase 2

Detailed Description:
high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars. According to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; We aimed to answer that whether we could achieve the same results from 70% TCA on atrophic varicella scars.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars
Study Start Date : March 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Objective Clearance(before and after photographies were taken)

Secondary Outcome Measures :
  1. Subjective Clearance(according to the patients satisfaction)
  2. Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Atrophic varicella scar on face

Exclusion Criteria:

  • Active varicella infection
  • Active Herpetic infection
  • Previous history of keloid formation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00422539

Contact: Behrooz Barikbin, M.D. 98-21-22744393 ext 5 bbarikbin@yahoo.com

Iran, Islamic Republic of
Skin Research Center, Shohada-e Tajrish Hospital, shaheed Beheshti Medical University Recruiting
Tehran, Iran, Islamic Republic of, 198994148
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Study Chair: Parviz Toossi, M.D. Skin Research Center of Shaheed Beheshti medical University
Principal Investigator: Behrooz Barikbin, M.D. Skin Research Center of Shaheed Beheshti Medical Universty

ClinicalTrials.gov Identifier: NCT00422539     History of Changes
Other Study ID Numbers: SRC-BBA-1385-6-1
First Posted: January 17, 2007    Key Record Dates
Last Update Posted: January 17, 2007
Last Verified: January 2007

Keywords provided by Shahid Beheshti University of Medical Sciences:
trichloroacetic acid
varicella scar

Additional relevant MeSH terms:
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Pathological Conditions, Anatomical